Latest Articles
SYS6043 Shows Initial Antitumor Activity in Pretreated Ovarian, Endometrial, and Cervical Cancer - OncLive
SYS6043 Shows Initial Antitumor Activity in Pretreated Ovarian, Endometrial, and Cervical Cancer OncLive
Published: April 12, 2026, 9:35 p.m.
Data From the CARE Trial in Recurrent/Advanced Endometrial Cancer - OncLive
Data From the CARE Trial in Recurrent/Advanced Endometrial Cancer OncLive
Published: April 12, 2026, 9:28 p.m.
Dr Yang on the Activity of Cadonilimab/Chemo in Recurrent/Advanced Endometrial Carcinoma - OncLive
Dr Yang on the Activity of Cadonilimab/Chemo in Recurrent/Advanced Endometrial Carcinoma OncLive
Published: April 12, 2026, 9:10 p.m.
Efficacy of Pamirtecan in HER2-Expressing Endometrial Cancer - OncLive
Efficacy of Pamirtecan in HER2-Expressing Endometrial Cancer OncLive
Published: April 12, 2026, 9:01 p.m.
Dr Pothuri on Preliminary Data With Trastuzumab Pamirtecan in HER2-Expressing Endometrial Cancer - OncLive
Dr Pothuri on Preliminary Data With Trastuzumab Pamirtecan in HER2-Expressing Endometrial Cancer OncLive
Published: April 12, 2026, 9 p.m.
Encouraging Activity in Poor-Risk Endometrial Cancer With HER2-Targeted Novel Drug - MedPage Today
Encouraging Activity in Poor-Risk Endometrial Cancer With HER2-Targeted Novel Drug MedPage Today
Published: April 12, 2026, 8:01 p.m.
A Look At BioNTech (BNTX) Valuation After Positive Phase 2 HER2 Endometrial Cancer Data - simplywall.st
A Look At BioNTech (BNTX) Valuation After Positive Phase 2 HER2 Endometrial Cancer Data simplywall.st
Published: April 12, 2026, 7:29 p.m.
Mocertatug Rezetecan Displays Early Efficacy, Tolerability in PROC and Endometrial Cancer - OncLive
Mocertatug Rezetecan Displays Early Efficacy, Tolerability in PROC and Endometrial Cancer OncLive
Published: April 12, 2026, 6:25 p.m.
Peer Support Helps Black Women With Endometrial Cancer Stay on Treatment - Cure Today
Peer Support Helps Black Women With Endometrial Cancer Stay on Treatment Cure Today
Published: April 12, 2026, 6:04 p.m.
BioNTech's Endometrial Cancer Data Signals Pivotal Pipeline Progress - AD HOC NEWS
BioNTech's Endometrial Cancer Data Signals Pivotal Pipeline Progress AD HOC NEWS
Published: April 12, 2026, 5:41 p.m.
Link copied to clipboard!